IPO filing research

Wella Co

Perfumes, Cosmetics & Other Toilet Preparations

ipo amended NYSE S-1

Wella Co IPO research page with SEC filing history, offering status, deal terms, structured filing extracts, company news, and comparable IPO context. Latest filing: S-1 on 2026-08-31. Current deal snapshot: exchange NYSE.

Filing Timeline

SEC EDGAR

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows DRS/A in the pre-IPO sequence.

common · Exchange NYSE · Use of proceeds to be used for general corporate purposes · Underwriters Goldman Sachs & Co. LLC, BofA Securities, KKR

Wella Co's S-1 filing highlights strong revenue growth, with net revenues increasing 9.2% to $2.94 billion in FY2026 compared to FY2025, driven by growth in Professional Hair, Retail Hair, and Styling Tools categories. Gross profit rose 9.1% to $2.01 billion, but SG&A expenses increased 7.7% due to advertising costs and foreign exchange impacts. Restructuring costs declined 19.4% to $29.4 million as major initiatives neared completion. Net income turned positive at $62.3 million in FY2026 after a $8.7 million loss in FY2025, with a significant drop in the effective tax rate from 120.4% to 24.9%. The company also recorded impairment charges of $84.2 million for intangible assets and $7.8 million for goodwill in FY2025.

2026-08-31 · 0001628280-26-059572

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS/A filing.

2026-08-03 · 0001628279-26-000961

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS/A filing.

2026-07-07 · 0001628279-26-000824

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS filing.

2026-06-03 · 0001628279-26-000686

DRS filed

Draft registration statement

Draft registration filed confidentially before the public launch.

First tracked pre-IPO filing for this issuer.

2026-04-17 · 0001628279-26-000484

Comparable Deals

20 comparable deals

Healthcare & BiotechLast 18 months

Only 0 strict matches; expanded to 20 using nearest neighbors.

Showing top 8 by similarity.

+5.8%

Median day-1

55%

Above issue

+10.6%

Median week-1

-20.9%

Downside (p10)

Vogenx, Inc. VOGX

2026-08-12 $81M Day 1: +0.0% Wk 1: +51.9%

same SIC grouprecent IPO

BlossomHill Therapeutics, Inc. BLSM

2026-08-07 $150M Day 1: +0.0% Wk 1: +2.2%

same SIC grouprecent IPO

Latigo Biotherapeutics, Inc. LTGO

2026-08-07 $346M Day 1: +1.4% Wk 1: +11.4%

same SIC grouprecent IPO

Braveheart Bio, Inc. BRVE

2026-08-06 $383M Day 1: +65.6% Wk 1: +45.3%

same SIC grouprecent IPO

Attovia Therapeutics, Inc. ATTO

2026-08-05 $269M Day 1: +28.8% Wk 1: +9.7%

same SIC grouprecent IPO

Apnimed, Inc. APMD

2026-07-31 $192M Day 1: +43.6% Wk 1: +74.3%

same SIC grouprecent IPO

Scribe Therapeutics, Inc. SCTX

2026-07-24 $129M Day 1: +44.3% Wk 1: +37.2%

same SIC grouprecent IPO

Standard Nuclear, Inc. STDN

2026-07-16 $150M Day 1: -8.2% Wk 1: -37.2%

same SIC grouprecent IPO

Recent News

No recent news stored for this issuer.